Hudson Bay Capital Management LP Arbutus Biopharma Corp Transaction History

Hudson Bay Capital Management LP

$21.9 Billion
Q3 2024

A detailed history of Hudson Bay Capital Management LP transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Hudson Bay Capital Management LP holds 1,030,000 shares of ABUS stock, worth $3.29 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

1,030,000

Previous 1,685,000 38.87%

Holding current value

$3.29 Million

Previous $5.21 Million 23.84%

% of portfolio

0.02%

Previous 0.03%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$3.12 - $4.56 $2.04 Million - $2.99 Million	-655,000 Reduced 38.87%	1,030,000 $3.97 Million
Q2 2024 Aug 14, 2024	SELL	$2.52 - $3.63 $4.63 Million - $6.66 Million	-1,835,382 Reduced 52.14%	1,685,000 $5.21 Million
Q1 2024 May 15, 2024	SELL	$2.26 - $2.92 $1.4 Million - $1.81 Million	-619,522 Reduced 14.96%	3,520,382 $9.08 Million
Q4 2023 Feb 14, 2024	SELL	$1.69 - $2.54 $16,900 - $25,400	-10,000 Reduced 0.24%	4,139,904 $10.3 Million
Q3 2023 Nov 14, 2023	BUY	$1.9 - $2.27 $2.48 Million - $2.96 Million	1,302,978 Added 45.77%	4,149,904 $8.42 Million
Q2 2023 Aug 14, 2023	BUY	$2.24 - $3.06 $247,520 - $338,130	110,500 Added 4.04%	2,846,926 $6.55 Million
Q1 2023 May 16, 2023	BUY	$2.23 - $3.1 $278,527 - $387,190	124,900 Added 4.78%	2,736,426 $8.29 Million
Q1 2023 May 15, 2023	SELL	$2.23 - $3.1 $4.99 Million - $6.94 Million	-2,239,890 Reduced 46.17%	2,611,526 $7.91 Million
Q4 2022 Feb 14, 2023	SELL	$1.91 - $2.85 $211,014 - $314,865	-110,479 Reduced 2.23%	4,851,416 $11.3 Million
Q3 2022 Nov 14, 2022	BUY	$1.88 - $2.88 $552,095 - $845,763	293,668 Added 6.29%	4,961,895 $9.48 Million
Q2 2022 Aug 12, 2022	BUY	$1.98 - $3.17 $366,102 - $586,133	184,900 Added 4.12%	4,668,227 $12.7 Million
Q1 2022 May 16, 2022	BUY	$2.42 - $3.98 $6.48 Million - $10.7 Million	2,677,627 Added 148.29%	4,483,327 $13.4 Million
Q4 2021 Feb 14, 2022	BUY	$3.11 - $4.61 $17,727 - $26,277	5,700 Added 0.32%	1,805,700 $7.02 Million
Q2 2021 Aug 16, 2021	BUY	$2.5 - $3.51 $1 Million - $1.4 Million	400,000 Added 28.57%	1,800,000 $5.45 Million
Q1 2021 May 14, 2021	BUY	$3.14 - $4.84 $2.12 Million - $3.27 Million	675,000 Added 93.1%	1,400,000 $4.66 Million
Q4 2020 Feb 12, 2021	BUY	$2.76 - $4.97 $41,400 - $74,550	15,000 Added 2.11%	725,000 $2.57 Million
Q3 2020 Nov 12, 2020	SELL	$1.75 - $6.2 $463,750 - $1.64 Million	-265,000 Reduced 27.18%	710,000 $2.22 Million
Q2 2020 Aug 12, 2020	BUY	$0.91 - $2.36 $159,250 - $413,000	175,000 Added 21.88%	975,000 $1.77 Million
Q1 2020 May 14, 2020	SELL	$1.01 - $3.42 $50,500 - $171,000	-50,000 Reduced 5.88%	800,000 $808,000
Q4 2019 Feb 12, 2020	SELL	$0.87 - $2.89 $39,150 - $130,050	-45,000 Reduced 5.03%	850,000 $2.36 Million
Q3 2019 Nov 13, 2019	BUY	$1.34 - $2.4 $13,400 - $24,000	10,000 Added 1.13%	895,000 $1.37 Million
Q2 2019 Aug 14, 2019	BUY	$1.46 - $4.44 $343,100 - $1.04 Million	235,000 Added 36.15%	885,000 $1.84 Million
Q4 2018 Feb 13, 2019	BUY	$3.5 - $9.66 $1.75 Million - $4.83 Million	500,000 Added 333.33%	650,000 $2.49 Million
Q3 2018 Nov 14, 2018	SELL	$7.85 - $12.35 $274,750 - $432,250	-35,000 Reduced 18.92%	150,000 $1.42 Million
Q2 2018 Aug 13, 2018	SELL	$5.0 - $7.35 $875,000 - $1.29 Million	-175,000 Reduced 48.61%	185,000 $1.35 Million
Q1 2018 May 14, 2018	SELL	$4.4 - $6.05 $176,000 - $242,000	-40,000 Reduced 10.0%	360,000 $1.8 Million
Q4 2017 Feb 12, 2018	BUY	$4.45 - $7.7 $1.25 Million - $2.17 Million	282,000 Added 238.98%	400,000 $2.02 Million
Q3 2017 Nov 13, 2017	BUY	$3.4 - $7.0 $401,200 - $826,000	118,000	118,000 $732,000

Others Institutions Holding ABUS

# of Institutions

155

Shares Held

99.5M

Call Options Held

2.31M

Put Options Held

525K

View Full List

About Arbutus Biopharma Corp

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $478M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

More about ABUS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

News

Stay updated on Hudson Bay Capital Management LP with notifications on news.

Account

Hudson Bay Capital Management LP Arbutus Biopharma Corp Transaction History